Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Fractures, Bone

ClinicalTrials.gov lists 3,429 trials for Fractures, Bone or a narrower condition beneath it. Zimmer Biomet has the most among industry and government lead sponsors, with 56.

MeSH D050723 Wounds and Injuries C26
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 59 Phase 1/2 Phase 1/2 30 Phase 2 Phase 2 103 Phase 2/3 Phase 2/3 28 Phase 3 Phase 3 123 Phase 4 Phase 4 262 Not applicable Not applicable 1,758 Observational Observational 1,064 Phase 1 Phase 1 59 Phase 1/2 Phase 1/2 30 Phase 2 Phase 2 103 Phase 2/3 Phase 2/3 28 Phase 3 Phase 3 123 Phase 4 Phase 4 262 Not applicable Not applicable 1,758 Observational Observational 1,064

Trials per phase (log scale)

2 more sections with rows

716 of the 3,429 trials are tagged with Fractures, Bone itself; the rest are tagged with a narrower condition beneath it.

Get the Fractures, Bone report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Fractures, Bone trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 258

1990: 2 trials (Not applicable 1, Phase 4 1) 1991: 2 trials (Observational 2) 1992: 2 trials (Observational 1, Phase 4 1) 1993: 2 trials (Observational 1, Phase 3 1) 1994: 1 trials (Observational 1) 1995: 3 trials (Observational 2, Not applicable 1) 1996: 1 trials (Not applicable 1) 1997: 2 trials (Observational 1, Phase 3 1) 1998: 9 trials (Observational 3, Not applicable 3, Phase 3 1, Phase 2 2) 1999: 6 trials (Not applicable 3, Phase 4 1, Phase 2/3 1, Phase 2 1) 2000: 9 trials (Observational 3, Not applicable 2, Phase 4 3, Phase 3 1) 2001: 10 trials (Observational 2, Not applicable 5, Phase 4 2, Phase 2 1) 2002: 23 trials (Observational 6, Not applicable 6, Phase 4 5, Phase 3 4, Phase 2 1, Phase 1/2 1) 2003: 26 trials (Observational 3, Not applicable 9, Phase 4 4, Phase 3 5, Phase 2 4, Phase 1/2 1) 2004: 27 trials (Observational 6, Not applicable 11, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 4, Phase 1/2 1) 2005: 37 trials (Observational 9, Not applicable 15, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 4, Phase 1 1) 2006: 56 trials (Observational 16, Not applicable 26, Phase 4 3, Phase 3 6, Phase 2/3 1, Phase 2 4) 2007: 76 trials (Observational 18, Not applicable 35, Phase 4 9, Phase 3 6, Phase 2/3 1, Phase 2 4, Phase 1 3) 2008: 96 trials (Other 1, Observational 31, Not applicable 35, Phase 4 11, Phase 3 5, Phase 2/3 1, Phase 2 8, Phase 1/2 2, Phase 1 2) 2009: 90 trials (Observational 26, Not applicable 40, Phase 4 13, Phase 3 4, Phase 2/3 4, Phase 2 1, Phase 1/2 1, Phase 1 1) 2010: 100 trials (Observational 30, Not applicable 43, Phase 4 11, Phase 3 7, Phase 2 6, Phase 1 3) 2011: 93 trials (Observational 33, Not applicable 37, Phase 4 7, Phase 3 7, Phase 2/3 2, Phase 2 6, Phase 1/2 1) 2012: 124 trials (Observational 42, Not applicable 55, Phase 4 12, Phase 3 9, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2013: 103 trials (Observational 31, Not applicable 51, Phase 4 8, Phase 3 3, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 1) 2014: 132 trials (Observational 38, Not applicable 69, Phase 4 5, Phase 3 6, Phase 2/3 1, Phase 2 7, Phase 1/2 4, Phase 1 2) 2015: 162 trials (Other 1, Observational 34, Not applicable 97, Phase 4 15, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 5) 2016: 146 trials (Observational 45, Not applicable 75, Phase 4 16, Phase 3 5, Phase 2/3 1, Phase 2 4) 2017: 166 trials (Observational 62, Not applicable 82, Phase 4 11, Phase 3 3, Phase 2 4, Phase 1/2 3, Phase 1 1) 2018: 188 trials (Observational 72, Not applicable 92, Phase 4 12, Phase 3 5, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2019: 205 trials (Observational 77, Not applicable 98, Phase 4 15, Phase 3 8, Phase 2 2, Phase 1/2 1, Phase 1 4) 2020: 199 trials (Observational 72, Not applicable 102, Phase 4 9, Phase 3 3, Phase 2/3 3, Phase 2 4, Phase 1/2 1, Phase 1 5) 2021: 236 trials (Observational 73, Not applicable 135, Phase 4 15, Phase 3 4, Phase 2/3 1, Phase 2 2, Phase 1 6) 2022: 226 trials (Observational 68, Not applicable 135, Phase 4 13, Phase 3 4, Phase 2 1, Phase 1/2 1, Phase 1 4) 2023: 228 trials (Observational 76, Not applicable 120, Phase 4 19, Phase 3 1, Phase 2 5, Phase 1/2 1, Phase 1 6) 2024: 258 trials (Observational 78, Not applicable 142, Phase 4 17, Phase 3 7, Phase 2/3 4, Phase 2 2, Phase 1/2 2, Phase 1 6) 2025: 195 trials (Observational 45, Not applicable 122, Phase 4 15, Phase 3 4, Phase 2 4, Phase 1/2 2, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 168
2025 195
2024 258
2023 228
2022 226
2021 236
2020 199
2019 205
2018 188
2017 166

Forecast of the full-year count, planned starts included, not rows of this table: about 200 trials starting in 2026 and about 210 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 275 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 1,974 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Fractures, Bone trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 59
Phase 1/2 30
Phase 2 103
Phase 2/3 28
Phase 3 123
Phase 4 262
Not applicable 1,758
Observational 1,064
Expanded access 1
Unknown 1

How many Fractures, Bone trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 161
Recruiting 351
Enrolling by invitation 39
Active, not recruiting 139
Completed 1,692

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Fractures, Bone trials? (1)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Zimmer Biomet 56

Which drugs are being tested for Fractures, Bone? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
+/- Bupivacaine HCl 41
DEXMEDETOMIDINE 20
PMI-150 (intranasal ketamine) 17

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ropivacaine 2 % 32
acid tranexamic 29
Transdermal Teriparatide 20
PO Morphine 18
Pericapsular Nerve Group (PENG) Block 18

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Fractures, Bone trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Study Fracture Related Complication 1,462 2
Other 1,304 5
Pneumonia 518 29
Other serious adverse event 378 1
Anaemia 337 12

Which publications cover Fractures, Bone? (1,992)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (28)

MeSH descendants one level down with at least one trial, most trials first.

+18 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages